Godfraind Théophile
Faculté de Médecine, Université Catholique de Louvain Laboratoire de Pharmacologie UCL5410, 1200 Bruxelles, Belgium.
Philos Trans R Soc Lond B Biol Sci. 2005 Dec 29;360(1464):2259-72. doi: 10.1098/rstb.2005.1774.
Drugs currently known as calcium channel blockers (CCB) were initially called calcium antagonists because of their ability to inhibit calcium-evoked contractions in depolarized smooth muscles. Blocking the entry of calcium reduces the active tone of vascular smooth muscle and produces vasodilatation. This pharmacological property has been the basis for the use of CCBs in the management of hypertension and coronary heart disease. A major question is whether drugs reducing blood pressure have other effects that help prevent the main complications of hypertension, such as atherosclerosis, stroke, peripheral arterial disease, heart failure and end-state renal disease. Experimental studies that focus on this question are reviewed in the present paper.
目前被称为钙通道阻滞剂(CCB)的药物最初被称为钙拮抗剂,因为它们能够抑制去极化平滑肌中钙诱发的收缩。阻断钙的进入可降低血管平滑肌的主动张力并产生血管舒张。这种药理特性一直是CCB用于治疗高血压和冠心病的基础。一个主要问题是,降低血压的药物是否还有其他作用有助于预防高血压的主要并发症,如动脉粥样硬化、中风、外周动脉疾病、心力衰竭和终末期肾病。本文综述了围绕这一问题展开的实验研究。